Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

NOACs Significantly Curb Risk of VTE in Cancer Patients

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

December 06, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

News Daily News

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

August 14, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

July 06, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

News Daily News

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

May 16, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

TCTMD’s Top 10 Most Popular Stories for March 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

April 02, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.